15 mg upadacitinib with steroid taper regimen achieved higher remission rate in adult GCA patients than placebo, per AbbVie's Phase 3 trial.

AbbVie reports positive Phase 3 SELECT-GCA study results for upadacitinib in giant cell arteritis treatment. Upadacitinib 15 mg in combination with a 26-week steroid taper regimen achieved the primary endpoint of sustained remission in adults with GCA, compared to a 29% success rate for patients receiving a placebo. Giant cell arteritis is an autoimmune disease causing inflammation in cranial and other arteries.